Furthermore, they showed that ONCOS-102 (an oncolytic adenovirus armed with Human GM-CSF and an Ad5/3 chimeric capsid) treatment promoted the infiltration of CD8+ T cells in the tumor, and its combined treatment with pembrolizumab significantly inhibited tumor growth (55). This evidence concerns the gene CSF2 and neoplasm.